| Literature DB >> 30787824 |
Ebtesam Mohammed Ba-Essa1, Sahar Abdulrhman1, Mayson Karkar2, Basima Alsehati1, Saleh Alahmad1, Ali Aljobran1, Abdulaziz Aldijwi1, Ali Alhawaj3.
Abstract
BACKGROUND: Tracking progress in diabetes care may help in evaluating the quality of efforts and identifying gaps in the care.Entities:
Keywords: Diabetes mellitus; key performance indicators; physician performance assessment; process and outcome indicators; quality improvement
Year: 2018 PMID: 30787824 PMCID: PMC6196706 DOI: 10.4103/sjmms.sjmms_86_17
Source DB: PubMed Journal: Saudi J Med Med Sci ISSN: 2321-4856
Guidelines modified from the American Diabetes Association recommendations for the management of diabetes patients (excluding pregnant women)
| Process measures | Frequency of assessment | Treatment goal or recommended outcome measures |
|---|---|---|
| HbA1c | Twice annually | <7% |
| Lipids | Annually, or more often if needed to achieve goals | LDL <100 mg/dl. In high-risk group with overt CVD, LDL <70 mg/dl. High-density lipoprotein >40 mg/dl, triglycerides <150 mg/dl[ |
| Blood pressure | Every routine visit | <140/90 mmHg |
| Calculated BMI | Every routine visit | <25 kg/m2[ |
| Comprehensive foot examination | Annually | NA |
| Serum creatinine, blood urea nitrogen, microalbuminuria or albumin-to-creatinine ratio | Annually | Either ACE inhibitors or ARBs (but not both in combination) are recommended for the treatment of patients with modestly elevated (30-299 mg/24 h) or higher levels (≥300 mg/24 h) of urinary albumin excretion |
| Dilated eye examination | Annually or every 2 years if no evidence of retinopathy | NA |
| Influenza vaccinations | Annually | NA |
| Aspirin therapy | 75-162 mg/day. As a primary prevention strategy in those with diabetes at increased cardiovascular risk that includes most men aged 50 years or women aged 60 years who have at least one additional major risk factor. As a secondary prevention strategy in those with diabetes with a history of CVD | |
| Diabetes education | At diagnosis (and as needed subsequently) | NA |
LDL – Low-density lipoprotein; CVD – Cardiovascular disease; ASCVD – Atherosclerotic cardiovascular disease; ACE – Angiotensin-converting enzyme; NA – Not applicable; ARB – Angiotensin receptor blocker; BMI – Body mass index; HbA1c – Glycated hemoglobin A1c
Algorithm 1Type 2 diabetes clinical pathway algorithm based on the American Diabetes Association's recommendations for management of diabetes patients (excluding pregnant women)
Proportion of patients with diabetes aged ≥14 years who received processes and intermediate outcomes of care for diabetes at Diabetes Center, Dammam Medical Complex
| Indicator | Baseline survey (2012) mean (%) | Final survey (2016) mean (%) | Absolute change (%) |
|---|---|---|---|
| BW measurement at each routine diabetes visit | 100 | 100 | 0 |
| BP measurement at each routine diabetes visit | 100 | 100 | 0 |
| HbA1c tests at least twice a year | 100 | 100 | 0 |
| Annual lipid profile test | 98 | 100 | 2 |
| Renal function test twice a year | 100 | 100 | 0 |
| Annual influenza immunization | 0 | 81 | 81 |
| Aspirin therapy as per recommendations | 86 | 98 | 12 |
| Annual urine examination for proteinuria | 78 | 97 | 19 |
| Annual comprehensive foot examination | 73 | 95 | 22 |
| Annual dilated eye examination | 98 | 97 | −1 |
| Personalized nutritional advice | 73 | 94 | 20 |
| Structured diabetes educational program | 55 | 98 | 43 |
| Documented self-monitoring of blood glucose | 58 | 85 | 27 |
| HbA1c level mean values | |||
| HbA1c level >9.0%* | 52 | 23 | −29 |
| HbA1c level <8.0% | 26 | 56 | 30 |
| HbA1c level <7.0% | 9 | 37 | 28 |
| LDL-C mean value | |||
| LDL-C <130 mg/dl (3.4 mmol/L) | 76 | 91 | 15 |
| LDL-C <100 mg/dl (2.6 mmol/L) | 52 | 74 | 22 |
| SBP mean values (SD) | |||
| BP <140/90 mmHg | 59 | 89 | 30 |
| BMI mean value (SD) | |||
| BMI 18.5-24.9 | 9 | 24 | 15 |
| BMI ≥25* | 91 | 73 | −18 |
*Inverse measure. BP – Blood pressure; HbA1c – Glycated hemoglobin A1c; LDL-C – Low-density lipoprotein cholesterol; SBP – Systolic blood pressure; BMI – Body mass index; SD – Standard deviation; BW – Body weight
Benchmarking key performance indicator measures (2012-2016) against peer organizations
| Indicator name | Achieved goals at DC-DMC (our results) | Benchmark | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2012 | 2013 | 2014 | 2015 | 2016 | KSA overall, 2006[ | Parts of KSA | UAE Dubai, 2004, 2010[ | USA | Australia, 2011[ | UK NHS, 2005, 2012[ | ||||
| Riyadh, 2009[ | Aseer, 2009[ | 2000s[ | Joslin Centre, 2007[ | 2010[ | ||||||||||
| Percentage with BW measured at each routine diabetes visit | 100 | 100 | 100 | 100 | 100 | - | 83 | 81 | 53 | - | - | - | 96 | 83 |
| Percentage with BP measured at each routine diabetes visit | 100 | 100 | 100 | 100 | 100 | - | 87 | 81 | 94 | - | 77 | - | 97 | 84 |
| Percentage with HbA1c tests at least twice a year | 100 | 100 | 100 | 99 | 100 | 84 | 96 | - | 84 | 72 | 98 | 56 | 92 | 93 |
| Percentage with Lipid profile tests at once a year | 98 | 100 | 100 | 98 | 100 | 14 | 93 | 39 | 78 | 62 | 61 | 88 | 76 | 81 |
| Percentage with renal function test every 6 months | 100 | 100 | 100 | 93 | 100 | - | - | 40 | - | - | - | - | 70 | 83 |
| Percentage who received influenza immunization | 0 | 67 | 77 | 79 | 81 | - | 0 | - | - | 53 | - | 60 | - | - |
| Percentage who received aspirin | 86 | 90 | 98 | 97 | 98 | - | - | 77 | - | 45 | 97 | - | 44 | - |
| Percentage examined for proteinuria at least once a year | 78 | 71 | 90 | 95 | 97 | 31 | 21 | 81 | - | 34 | 38 | - | 65 | 35 |
| Percentage with comprehensive foot exam at least once a year | 73 | 77 | 83 | 81 | 95 | 36 | 37 | - | 70 | 68 | 74 | 71 | 35 | - |
| Percentage with dilated eye exam at least once a year | 98 | 97 | 100 | 93 | 97 | 31 | 81 | 86 | 53 | 63 | 35 | 73 | 41 | 83 |
| Percentage who received personalized nutritional advice | 73 | 88 | 93 | 94 | 94 | - | - | 82 | - | - | - | - | - | - |
| Percentage who received a structured educational program | 55 | 64 | 79 | 100 | 98 | 45 | 52 | 82 | - | 55 | - | 55 | - | - |
| Percentage with glucose home monitoring as indicated | 58 | 80 | 78 | 95 | 85 | - | - | - | - | 55 | - | 71 | - | - |
| Percentage with HbA1c level >9.0% (poor control) (inverse measure) | 52 | 37 | 42 | 32 | 23 | - | - | - | 21 | 21 | - | 13 | 43 | - |
| Percentage with HbA1c level <8.0% (internal benchmark) | 26 | 48 | 46 | 51 | 56 | - | - | - | - | 47 | 57 | 79 | 27 | 21 |
| Percentage with HbA1c level <7.0% (optimal control) | 9 | 22 | 23 | 26 | 37 | 27 | 10 | 21 | 32 | 42 | - | 52 | 38 | 36 |
| Percentage with LDL-C <130mg/dl (3.4 mmol/L) | 76 | 83 | 89 | 88 | 91 | - | - | - | 65 | 64 | 74 | - | 88 | 37 |
| Percentage with LDL-C <100mg/dl (2.6 mmol/L) | 52 | 55 | 56 | 65 | 74 | 35 | 28 | - | 34 | 34 | 32 | 57 | 66 | - |
| Percentage with BP <140/90 mmHg | 59 | 67 | 54 | 82 | 89 | 16 | 19 | 29 | 41 | 68 | 61 | 51 | 76 | 46 |
| Percentage within targeted BMI of 18.5-25 | 18.5 | 9 | 15 | 24 | 24 | - | 8 | 17 | 25 | 66 | - | - | 19 | 59 |
| Percentage with BMI >25 | 91 | 78 | 87 | 75 | 73 | - | 92 | 84 | 75 | - | - | 52 | 81 | - |
BP – Blood pressure; HbA1c – Glycated hemoglobin A1c; LDL – Low-density lipoprotein cholesterol; BMI – Body mass index; BW – Body Weight; DC-DMC – Diabetes Center – Dammam Medical Complex
Chart 1Physician performance mean compliance with the guidelines and intermediate outcomes of care for diabetes as compared with target, 2012–2016